CNBC
Novo Nordisk shares dive 9% after heart medicine fails trial
Friday, July 31, 2026
Novo Nordisk's stock price fell 9 percent following the announcement that one of its heart medications failed to meet its primary endpoint in a clinical trial. The company did not disclose additional details about which drug was involved or the specifics of the trial results in the immediate announcement. Novo Nordisk has a portfolio of cardiovascular medicines in development. The stock decline reflects investor concern about the failed trial outcome.
Original reporting: https://www.cnbc.com/2026/07/31/novo-nordisk-trial-results.html